Skip to main content

Table 3 Effects of clinical variables on the TLR levels in lupus patients (continuous variable)

From: Antagonist-mediated down-regulation of toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus

  TLR3 TLR7 TLR8 TLR9
  n r P n r P n r P n r P
Clinical characteristic             
   SLE duration, year 46 -0.263 0.279 26 -0.187 0.214 46 0.183 0.222 46 0.064 0.672
   SLEDAI score 46 -0.004 0.977 26 -0.030 0.885 46 0.161 0.284 46 0.446 0.002 ††
   Anti-dsDNA titer (> 100 IU/ml) 19 0.272 0.261 13 -0.291 0.334 19 0.498 0.030 19 -0.094 0.702
Immunosuppressive therapy             
   Prednisolone             
   Current dose, mg 36 -0.082 0.636 22 -0.164 0.466 36 0.116 0.502 36 -0.032 0.855
   Cumulative dose, gm 38 -0.020 0.898 22 -0.436 0.042 38 0.102 0.542 38 0.018 0.916
   Duration, months 38 -0.150 0.368 22 -0.223 0.318 38 -0.100 0.555 38 0.017 0.920
   Hydroxychloroquine             
   Current dose, mg 16 0.261 0.329 10 -0.044 0.905 16 -0.226 0.400 16 0.052 0.848
   Cumulative dose, gm 27 -0.073 0.716 15 -0.132 0.639 27 -0.193 0.335 27 -0.399 0.039
   Duration, months 27 -0.106 0.598 15 -0.179 0.524 27 -0.139 0.488 22 -0.081 0.689
   Azathioprine             
   Current dose, mg 8 -0.385 0.346 5 -0.671 0.215 8 0.462 0.249 8 -0.089 0.833
   Cumulative dose, gm 25 -0.166 0.429 16 -0.012 0.966 25 -0.336 0.101 25 -0.339 0.098
   Duration, months 25 -0.036 0.865 16 -0.118 0.664 25 -0.396 0.505 25 -0.440 0.028
   Cyclophosphamide (oral or IV)             
   Current dose, mg 4 -0.316 0.684 2 N.A. N.A. 4 -0.316 0.684 4 -0.316 0.684
   Cumulative dose, gm 7 0.107 0.840 3 N.A. N.A. 7 -0.107 0.840 7 -0.500 0.267
   Duration, months 7 0.571 0.200 3 N.A. N.A. 7 0.143 0.783 7 -0.393 0.396
   Cyclosporin A             
   Current dose, mg - - - - - - - - - - - -
   Cumulative dose, gm 9 0.783 0.013 5 0.800 0.133 9 -0.333 0.948 9 -0.283 0.463
   Duration, months 9 0.200 0.613 5 0.900 0.083 9 0.167 0.678 9 0.333 0.385
   Mycophenolate mofetil, gm             
   Current dose, mg 5 0.359 0.553 3 N.A. N.A. 5 0.718 0.872 5 0.564 0.322
   Cumulative dose, gm 8 0.071 0.935 5 -0.600 0.350 8 -0.429 0.299 8 -0.381 0.360
   Duration, months 8 -0.048 0.935 5 -0.700 0.233 8 -0.548 0.171 8 -0.429 0.299
  1. Anti-dsDNA, Anti-double stranded DNA; SLE, systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus disease activity index; TLR, toll-like receptor; P <0.05, †† P <0.01.